References
- Yarden Y, Kuang W J, Yang-Feng T, Coussens L, Munemitsu S, Dull T J, et al. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO Journal 1987; 6: 3341–3351
- Qui F H, Ray P, Brown K, Barker P E, Jhanwar S, Ruddle F H, et al. Relationship with the CSF-1/PDGF receptor kinase family—oncogene activation of v-kit involves deletion of extracellular domain and C terminus. EMBO Journal 1988; 7: 1003–1011
- Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayana H, Ishikawa J, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991; 78: 2962–2968
- Brach M A, Buhring H J, Grub H G, Ashman L K, Ludwig W F, Mertelsmann R H, et al. Functional expression of c-kit by acute myelogenous leukemia blasts is enhanced by tumor necrosis factor-α through posttranscriptional mRNA stabilization by a labile protein. Blood 1992; 80: 1224–1230
- Turner A M, Zsebo K M, Martin F, Jacobsen F W, Bennett L G, Broudy V C. Nonhematopoietic cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80: 374–381
- Ashman L K. The biology of stem cell factor and its receptor c-kit. International Journal of Biochemical Cell Biology 1999; 31: 1037–1051
- Demetri G D, von Mehren M, Blanke C D, Van den Abbeele A D, Eisenberg B, Roberts P J, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 2002; 347: 472–480
- Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonei V, Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30 + anaplastic large cell lymphomas. Blood 1994; 83: 785–792
- Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kankura Y. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China. Cancer Research 2000; 60: 2345–2347
- Melnyk A, Rodrguez A, Pugh W C, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520
- Hoshida Y, Hongyo T, Nakatsuka S, Nishiu M, Takakuwa T, Tomita Y, et al. Gene mutations in lymphoproliferative disorders of T and NK/T cell phenotypes developing in renal transplant patients. Laboratory Investigations 2002; 82: 257–264
- Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999; 17: 3835–3849
- Harris N L, Jaffe E S, Stein H, Banks P M, Chan J KC, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
- Brauns T C, Schultewolter T, Dissemond J, Maschke J, Goos M. C-KIT expression in primary cutaneous T-cell lymphomas. Journal of Cutaneous Pathology 2004; 31: 577–582
- Tarn C, Merkel E, Canutescu A A, Shen W, Skorobogatko Y, Heslin M J, et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clinical Cancer Research 2005; 11: 3668–3677